Cancer Monoclonal Antibodies Market (By Type: Chimeric Antibodies, Humanized Antibodies; By Application: Blood Cancer, Breast Cancer; Lung Cancer; By End-user) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Cancer Monoclonal Antibodies Market 

5.1. COVID-19 Landscape: Cancer Monoclonal Antibodies Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Cancer Monoclonal Antibodies Market, By Type

8.1. Cancer Monoclonal Antibodies Market, by Type, 2022-2030

8.1.1 Humanized

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Human

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Chimeric

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Murine

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Cancer Monoclonal Antibodies Market, By Application

9.1. Cancer Monoclonal Antibodies Market, by Application, 2022-2030

9.1.1. Blood Cancer

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Breast Cancer

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Lung Cancer

9.1.3.1. Market Revenue and Forecast (2017-2030)

9.1.4. Melanoma

9.1.4.1. Market Revenue and Forecast (2017-2030)

9.1.5. Colorectal Cancer

9.1.5.1. Market Revenue and Forecast (2017-2030)

9.1.6. Liver Cancer

9.1.6.1. Market Revenue and Forecast (2017-2030)

9.1.7. Others

9.1.7.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Cancer Monoclonal Antibodies Market, By End-user 

10.1. Cancer Monoclonal Antibodies Market, by End-user, 2022-2030

10.1.1. Hospitals

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Research Institutes

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Cancer Monoclonal Antibodies Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.3. Market Revenue and Forecast, by End-user (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.1.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.6.3. Market Revenue and Forecast, by End-user (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.2.7.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.6.3. Market Revenue and Forecast, by End-user (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.3.7.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.6.3. Market Revenue and Forecast, by End-user (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Type (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Application (2017-2030)

11.4.7.3. Market Revenue and Forecast, by End-user (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.3. Market Revenue and Forecast, by End-user (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.4.3. Market Revenue and Forecast, by End-user (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Type (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Application (2017-2030)

11.5.5.3. Market Revenue and Forecast, by End-user (2017-2030)

Chapter 12. Company Profiles

12.1. F. Hoffmann-La Roche Ltd.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Bristol Myers Squibb Co.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Merck & Co.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. GlaxoSmithKline plc

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Johnson & Johnson

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Amgen, Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Novartis AG

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. AstraZeneca plc

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Eli Lilly and Company

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. AbbVie

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Report Details

  • Report Code:39431
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Published:August 2022
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers